MedTrace Logo

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

NCT05737706 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2025-04-06

No results posted yet for this study

Summary

A Phase 1/2 study of MRTX1133 in solid tumors harboring a KRAS G12D mutation.

Conditions

Interventions

DRUG

MRTX1133

KRAS G12D Inhibitor

Sponsors & Collaborators

  • Mirati Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-06
Primary Completion
2025-03-10
Completion
2025-03-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05737706 on ClinicalTrials.gov